Age Related Macular Degeneration Market to Reach $16.2 Billion, Globally, by 2033 at 5% CAGR

The age related macular degeneration market was valued at $10.0 billion in 2023, and is estimated to reach $16.2 billion by 2033, growing at a CAGR of 5%.

PORTLAND, OR, UNITED STATES, December 16, 2024 /EINPresswire.com/ -- Allied Market Research published a report, titled, "Age Related Macular Degeneration Market by Drug Type (Aflibercept, Ranibizumab and Others), Disease Type (Wet Age Related Macular Degeneration (AMD), Dry Age Related Macular Degeneration (AMD)) and Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2024-2033". According to the report, the age related macular degeneration market was valued at $10.0 billion in 2023, and is estimated to reach $16.2 billion by 2033, growing at a CAGR of 5% from 2024 to 2033.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐑𝐞𝐩𝐨𝐫𝐭 -
https://www.alliedmarketresearch.com/request-sample/A201849

Prime determinants of growth

Rise in prevalence of age-related macular degeneration cases and rise in geriatric population are the major factors that drive the growth of the age-related macular degeneration market. However, high cost of treatment hinders the market growth. Moreover, technological advancements offer remunerative opportunities for the expansion of the global age-related macular degeneration market.

Segment Highlights

The aflibercept drug are widely used

By drug type, the Aflibercept (Eylea) segment is widely used for treating wet age-related macular degeneration (AMD) due to its effectiveness in inhibiting vascular endothelial growth factor (VEGF) . This action prevents abnormal blood vessel growth and leakage in the eye, helping to maintain vision and slow disease progression. Its proven efficacy and safety profile make it a preferred choice among clinicians.

Prevalence of Wet Age-Related Macular Degeneration (AMD)

By disease type, the wet age-related macular degeneration (AMD) segment has a significant market share owing to it being increasingly prevalent, particularly among the aging population. Characterized by abnormal blood vessel growth under the retina, it leads to rapid vision loss. The rising incidence highlights the need for effective treatments, such as anti-VEGF therapies, to manage and slow disease progression.

Hospitals pharmacies are the major distributors

By distribution channel, the hospital pharmacies segment plays a pivotal role in distributing drugs for age-related macular degeneration (AMD), ensuring timely access for patients. They manage inventory, fill prescriptions, and provide counseling. AMD drugs, like anti-VEGF injections, require careful handling and administration. Hospital pharmacies ensure proper storage and delivery, optimizing treatment outcomes for patients with AMD, a condition affecting central vision in older adults.

𝐏𝐫𝐨𝐜𝐮𝐫𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 (𝟐𝟐𝟎 𝐏𝐚𝐠𝐞𝐬 𝐏𝐃𝐅 𝐰𝐢𝐭𝐡 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬, 𝐂𝐡𝐚𝐫𝐭𝐬, 𝐓𝐚𝐛𝐥𝐞𝐬, 𝐚𝐧𝐝 𝐅𝐢𝐠𝐮𝐫𝐞𝐬) @
https://www.alliedmarketresearch.com/age-related-macular-degeneration-market/purchase-options

Regional Outlook

In North America and Europe, the age-related macular degeneration (AMD) drugs market is robust due to high prevalence and advanced healthcare infrastructure. Asia-Pacific shows promising growth driven by rising elderly population and improving healthcare access. Latin America and Middle East/Africa regions exhibit steady growth, supported by increasing awareness and healthcare investments.

Major Key Players -

Regeneron Pharmaceuticals Inc.

Novartis AG

F. Hoffmann-La Roche Ltd.

Biogen

Bayer AG

Coherus Biosciences Inc

Sanofi

Apellis Pharmaceuticals

Bausch Health Companies Inc.

Ionis Pharmaceuticals, Inc

The report provides a detailed analysis of these key players in the global age-related macular degeneration market. These players have adopted different strategies such as expansion, product approval, product launch and others to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.

Recent Industry Development

In September 2021, Samsung Bioepis Co., Ltd., and Biogen Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Byooviz (ranibizumab-nuna), a biosimilar referencing Lucentis (ranibizumab) for the treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV) .

In January 2022, Roche announced that the U.S. Food and Drug Administration (FDA) has approved Vabysmo (faricimab-svoa) for the treatment of neovascular or wet age-related macular degeneration (nAMD) and diabetic macular edema (DME) . Neovascular AMD and DME are two leading causes of vision loss across the globe.

Frequently Asked Questions?

Q1. What is the total market value of Age Related Macular Degeneration Market report ?

Q2. What would be forecast period in the market report?

Q3. What is the market value of Age Related Macular Degeneration Market in 2032?

Q4. Which is base year calculated in the Age Related Macular Degeneration Market report?

Q5. Which are the top companies hold the market share in Age Related Macular Degeneration Market ?

Q6. Which is the most influencing segment growing in the Age Related Macular Degeneration Market report?

About Us -

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various research data tables and confirms utmost accuracy in our market forecasting. Each and every us companies and this helps us in digging out market data that helps us generate accurate y data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa
Allied Market Research
+1 800-792-5285
email us here
Visit us on social media:
Facebook
X